The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Cardio-oncology guidelines for BTKi toxicities in CLL: how are they used in clinical practice?
Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the guidelines surrounding cardiovascular toxicity associated with BTK inhibitors (BTKis), which suggest that a grade 3 event or higher should encourage clinicians to alter drug dosing. Dr Ahn also reflects on the need to better understand BTKi cardiovascular toxicities. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
